” Even though the Ricaurte Tale was unfolding, MAPS finally acquired FDA indicator-off on the protocol for human trials of MDMA as a treatment method for PTSD, but only immediately after it procured a $one million insurance policies policy to indemnify the review board.Molly holds the track record of remaining an unadulterated drug—Ecstasy minu